… Imatinib is metabolised predominantly by CYP3A4 to the N-desmethyl metabolite (CGP74588),
which is the major circulating active metabolite [80], [81]. Its in vitro potency is similar to …

Several cancer treatments are shifting from traditional, time-limited, nonspecific cytotoxic
chemotherapy cycles to continuous oral treatment with specific protein-targeted therapies. In …

Most anticancer drugs are characterised by a steep dose–response relationship and narrow
therapeutic window. Inter-individual pharmacokinetic (PK) variability is often substantial. …

… We designed a new series of substituted 2‐piperazino‐benzothiazinones (PBTZs), which
allowed extensive SAR studies through variation of the piperazine N‐4 substituents, which …

The treatment of some cancer patients has shifted from traditional, non-specific cytotoxic
chemotherapy to chronic treatment with molecular targeted therapies. Imatinib mesylate, a …

Aims The aims of this observational study were to assess the variability in imatinib
pharmacokinetics and to explore the relationship between its disposition and various biological …

Therapeutic drug monitoring (TDM) aims to optimize treatments by individualizing dosage
regimens based on the measurement of blood concentrations. Dosage individualization to …

Importance Although negative associations of COVID-19 pandemic high school closures
with adolescents’ health have been demonstrated repeatedly, some research has reported a …

Bonding to enamel has over 50 years of history. Efforts have been made to develop or
introduce a simplified alternative, but enamel acid etching remains the most effective procedure …

Therapeutic drug monitoring (TDM) can be defined as the measurement of drug in biological
samples to individualise treatment by adapting drug dose to improve efficacy and/or reduce …